RAS GTPase inhibitor 1

CAS No. 2252242-32-1

RAS GTPase inhibitor 1( —— )

Catalog No. M33100 CAS No. 2252242-32-1

RAS GTPase inhibitor 1 is a RAS GTPase inhibitor with potential antitumor activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 848 Get Quote
10MG 1159 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    RAS GTPase inhibitor 1
  • Note
    Research use only, not for human use.
  • Brief Description
    RAS GTPase inhibitor 1 is a RAS GTPase inhibitor with potential antitumor activity.
  • Description
    RAS GTPase inhibitor 1 (example 51) is a RAS GTPase inhibitor with anti-tumor activity, extracted from patent WO2018212774A1. RAS GTPase inhibitor 1 (example 51) exhibits an EC50 less than 1 μM for at least one nucleotide exchange and an IC50 less than 1 μM in H727 cells.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    Raf
  • Recptor
    Raf
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2252242-32-1
  • Formula Weight
    565.99
  • Molecular Formula
    C27H28ClF4N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C(O)=O)(F)(F)F.N([C@H](CC)C1CC1)C=2C3=C(C(=CC=C3)C=4CCNCC4)N=C(NC5=CC(Cl)=C(F)C=C5)N2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. WATERSON, Alex G, et al. QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING. Patent. WO2018212774A1.
molnova catalog
related products
  • LUT014

    LUT014 is a B-Raf inhibitor (IC50: 11.7 nM) and developed to decrease dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.

  • B-Raf IN 16

    B-Raf IN 16, a BRAF inhibitor, belongs to cyclic iminopyrimidine derivatives and can be used for cancer or tumour research.

  • REDX-05358

    REDX-05358 is a novel potent, highly selective, orally bioavailable pan RAF inhibitor.